Skip to main content

Chemoprevention of Lung Pathologies by Dietary n-3 Polyunsaturated Fatty Acids

Buy Article:

$63.00 plus tax (Refund Policy)

Different intervention trials have been so far conducted and others are ongoing to evaluate the effect of increased intake of n-3 polyunsaturated fatty acids (PUFAs) in the prevention of several disorders affecting lungs and airways. They have been focused on chronic obstructive pulmonary disease, acute respiratory distress syndrome, acute lung injury, pulmonary fibrosis, alteration of lung function in cystic fibrosis, as well as asthma and cachexia in lung cancer patients. Their outcomes are not always consistent, but, if beneficial effects were observed, they have been related mainly to the anti-inflammatory action of n-3 PUFAs. On the contrary, trials investigating their effects on the development and progression of lung cancer are still not available. This in spite of the huge number of equivalent studies performed on other kind of cancers (breast, colon and prostate cancer), which share with lung cancer the highest incidence in Western countries and an elevated sensitivity to chemoprevention. Contrasting results were also obtained by the few epidemiological studies available on lung cancer. However, different experimental studies, performed in vivo and in vitro, provided strong indications of the anti-tumor action of n-3 PUFAs against lung cancer, and identified molecular mechanisms for their action. In this review our effort will concentrate in critically reviewing the current evidence for the beneficial effect of n-3 PUFAs in inflammatory and neoplastic disorders of lungs and airways, and in identifying possible molecular mechanisms underlying their effects.

No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: (ALI); (ARDS); (CFTR); (COPD); (NF-B); (PPAR-); (cftr/ mice); ALI; ARDS; COPD; Caenorhabditis elegans; Caucasians; Chemoprevention; Docosanoids; Eicosanoid; Eicosapentaenoic acid; IL-8; LUNG CANCER; Lung injury; Polyunsaturated Fatty Acids; Tumor Necrosis Factor; acute respiratory distress syndrome; airway inflammation; anti-inflammatory; asthma; cachexia; cancer; chemotherapy; cystic fibrosis; docosahex-aenoic acid; fat-1; inflammation; interstitial lung diseases; interstitial lung diseases, lung; linolenic acid; lung; lung cancer; lung injury; maresins; n-3 PUFAs; pathology; protectins; pulmonary fibrosis; resolvins; smokin

Document Type: Research Article

Publication date: 2010-10-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more